Volastra
Derek Cogan is an accomplished chemist with extensive experience in the biotechnology sector, currently serving as Vice President of Chemistry at Volastra Therapeutics since October 2019, after holding the position of Senior Director of Chemistry. Prior to this, Derek held the role of Director of Chemistry at Quentis Therapeutics, Inc. from August 2018 to October 2019 and served as Principal Scientist in Chemistry at Bioverativ from April 2017 to July 2018. Derek's career began at Boehringer Ingelheim Pharmaceuticals, where a tenure from 2002 to 2017 included roles as Senior Principal Scientist, Principal Scientist, and Senior Scientist. Academically, Derek obtained a Ph.D. in Chemistry from the University of California, Berkeley, and a BS in Chemistry from Boston College, with additional education at UC Irvine.
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.